



The University of
Nottingham

UNITED KINGDOM · CHINA · MALAYSIA

Bee, Janet and Fuller, Sharon and Miller, Suzanne and Johnson, Simon R. (2017) Lung function response and side effects to rapamycin for lymphangiomyomatosis: a prospective national cohort study. *Thorax* . ISSN 0040-6376

Access from the University of Nottingham repository:

<http://eprints.nottingham.ac.uk/47947/1/Bee%20at%20a%20manuscript%20R1%20clean.pdf>

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study.

J Bee¹, S Fuller¹, S Miller², SR Johnson^{1,2†}.

1. National Centre for lymphangioleiomyomatosis, Nottingham, UK.
2. Division of Respiratory Medicine, Nottingham Molecular Pathology Node and Nottingham Biomedical Research Centre, University of Nottingham, UK.

† Author for correspondence.

Professor Simon Johnson

Division of Respiratory Medicine, University of Nottingham.

Respiratory Medicine, D Floor, South Block.

Queens Medical Centre.

Nottingham.

NG7 2UH, U.K.

simon.johnson@nottingham.ac.uk

What is the key question?

How can we best optimise the risk / benefit balance of mTOR inhibition for loss of lung function in individuals with LAM?

What is the bottom line?

Loss of lung function may continue in some individuals treated with rapamycin and a poor response to the drug is more likely in those with lower lung function and longer disease duration at the start of treatment. Lower levels of rapamycin are associated with fewer side effects but equal benefit compared with higher levels.

Why read on?

We have used a prospective national cohort study to understand the relationship between rapamycin levels, lung function response and side effects to improve the use of mTOR inhibitors in women with LAM.

Abstract

Rationale mTOR inhibitors reduce loss of lung function in LAM although their benefit varies between individuals. We examined lung function response and side effects to rapamycin in a national cohort.

Methods Subjects were receiving rapamycin for progressive lung disease. Clinical evaluation, detailed phenotyping, serial lung function, rapamycin and safety monitoring were performed according to a clinical protocol. Lung function change, measured as FEV₁ slope (Δ FEV₁), was reported for those treated for one year or longer.

Results Rapamycin was associated with improved Δ FEV₁ in 21 individuals where pre-treatment data were available ($p < 0.0001$). In 47 treated for a mean duration 35.8 months, mean Δ FEV₁ was +11 (SD 75) ml/yr although varied from +254 to -148 ml/yr. The quartile with the highest positive Δ FEV₁ had greater pre-treatment FEV₁ ($p = 0.02$) and shorter disease durations ($p = 0.02$) than the lowest quartile. Serum rapamycin level was positively associated with side effects ($p = 0.02$) but not Δ FEV₁ over one year. Within the first month of therapy, aphthous ulcers, nausea and diarrhoea were associated with higher rapamycin levels. Acne, oedema and menstrual irregularities tended to increase over the first year of therapy. At the end of observation the prevalence of side effects was 5% or less.

Conclusions Rapamycin reduces lung function loss in LAM, although in some Δ FEV₁ continues to fall at an accelerated rate. Poor response to rapamycin was associated with lower pre-treatment lung function and longer disease duration but not serum level. Early intervention with low dose rapamycin may preserve lung function and reduce side effects.

Introduction.

Lymphangiomyomatosis (LAM) is a multisystem disease characterised by lung cysts, lymphatic abnormalities and a high prevalence of kidney angiomyolipomas¹. As a sporadic disease LAM affects almost exclusively women with an incidence of 0.3 per million women per year: however LAM is common in the autosomal genetic disease tuberous sclerosis complex (TSC-LAM) where it affects around half of adult women and some men². In LAM, cysts replace the lung parenchyma resulting in recurrent pneumothorax and dyspnoea which can progress over a variable period of years to result in respiratory failure. Lymphatic involvement can cause lymphatic masses and chylous collections in the thorax and abdomen.

Angiomyolipomas are frequently small and asymptomatic but may enlarge and bleed necessitating urgent treatment.

The lungs and lymphatics of women with LAM are infiltrated by LAM cells; a clone of cells expressing markers of both melanogenesis and smooth muscle differentiation. LAM cells in both sporadic and TSC-LAM have bi-allelic inactivating mutations in either the TSC-1, or more frequently the TSC-2 gene³. Loss of function of TSC-1/2 leads to constitutive activation of the mechanistic target of rapamycin (mTOR) resulting in altered translation of 5 prime cap dependent genes, uncontrolled proliferation, dependence on autophagy and a metabolic shift toward energy generation by glycolysis⁴. Suppression of mTOR signalling in women with LAM is associated with reduced loss of lung function⁵⁻⁷, reduction in angiomyolipoma volume⁸⁻¹⁰ and reduced chylous complications¹¹. The use of mTOR inhibitors has become the standard of care for progressive lung disease in sporadic LAM¹² and in TSC for LAM, angiomyolipoma and sub-ependymal giant cell astrocytoma¹³.

Although mTOR inhibitors reduce the rate of loss of FEV₁ in those with progressive disease, some of those treated continue to decline and it is not clear how to manage these individuals^{14 15}. Further, mTOR inhibition is associated with oral mucositis, nausea, diarrhoea, oedema, acne, hyperlipidaemia, proteinuria, pneumonitis and a theoretical risk of future malignancy¹⁴. As many women with LAM develop progressive disease in their thirties, the potential cumulative exposure to mTOR inhibitors over decades means the risk of adverse effects is significant. Although data from clinical trials and selected populations have reported clinical response and side effects^{7 16} how these are related to drug levels has not been examined. As LAM is an orphan disease with no surrogate markers of disease activity, performing conventional randomised studies to understand different treatment regimens requires international collaborations over many years at potentially prohibitive cost. To address how to best preserve lung function, limit side effects from mTOR inhibition and inform future clinical trial design, we used a prospective national cohort study of women with LAM treated with rapamycin for progressive lung disease over a period of one to six years study to examine the relationship between lung function response, side effect profile and clinical features.

Methods

The study was conducted at the National Centre for Lymphangiomyomatosis at Nottingham University Hospitals NHS Trust between 2011 and 2017. The Centre is funded by highly specialised commissioning for NHS England to provide a comprehensive clinical service for women with LAM in the UK. Women receiving care at the LAM Centre are invited to participate in an observational cohort study. The study was approved by the East Midlands Research Ethics Committee (13/EM/0264) and all participants gave written informed consent.

The diagnosis of LAM was made according to American Thoracic Society criteria¹². Clinical history, lung function, imaging and blood samples were collected at recruitment. Duration of disease was calculated as the interval between the first symptom attributable to LAM (e.g. first pneumothorax or onset of dyspnoea) and the start of treatment with rapamycin.

All subjects had progressive lung disease. The decision to start rapamycin was made on clinical grounds alone. Subjects were treated according to a standard clinical protocol: individuals had baseline full blood count, urea and electrolytes, liver function tests, lipid profile, urine protein / creatinine ratio (PCR) and a pregnancy test. All were counselled on the indication for treatment, need for monitoring, potential adverse effects and drug interactions. Advice was given around intercurrent illness, surgery, pregnancy and supported with written information. All were given contact details of the Centre nurse specialist for queries and advice.

Rapamycin, generally one or two mg orally once daily, was prescribed and a trough level measured 10 – 14 days later. One month later, subjects returned for a clinical assessment of side effects, a trough rapamycin level, full blood count, urea and electrolytes, liver function tests, lipid profile, urine protein / creatinine ratio and the dose adjusted on the basis of serum level or side effects if required. After three months, these tests were repeated and FEV₁ and DL_{CO} measured. This assessment was repeated at six months of treatment and every six months thereafter. Subjects saw both a consultant physician (SJ) and nurse specialist (SF) at each visit and side effects were recorded.

Lung function was measured according to ATS/ERS standards¹⁷ with predicted values calculated using regression equations from Quanjer et al.¹⁸. Change in FEV₁ over time (Δ FEV₁) was calculated as the regression slope of all FEV₁ measurements taken either before rapamycin or during treatment using Microsoft Excel as described¹⁹. As shorter periods of observation and fewer individual measurements are associated with variation away from the group mean for Δ FEV₁ in those with LAM¹⁹, Δ FEV₁ was only reported for periods of observation of 1 year or greater. Serum vascular endothelial growth factor-D (VEGF-

D) was measured using a human quantikine VEGF-D ELISA (R & D Systems, UK). Serum cholesterol, urea and electrolytes, full blood count, liver function and urine PCR were measured in the clinical service laboratory at Nottingham University NHS Trust.

Data were analysed in GraphPad Prism version 7.03 (GraphPad Software, La Jolla, CA USA), MS Excel and SPSS version 24 (IBM Corporation, Armonk, NY USA). Data were tested for normality using the D'Agostino-Pearson test. Paired Δ FEV₁ values before and after therapy were compared by paired t-test, comparison of cholesterol and PCR before and after treatment by paired t-test for the individual subjects, non-parametric data by Fischer's exact and Chi square tests and association of rapamycin level with side effects and laboratory markers by Pearson correlation. T-tests were reported uncorrected unless stated. Comparison of pre-treatment disease duration and lung function, drug level and phenotype characteristics with Δ FEV₁ was performed for the quartiles with the best and poorest response to rapamycin by unpaired t-tests and for the group as a whole by multivariate analysis. P values of <0.05 were considered significant.

Results

Study cohort

Forty-seven women with definite LAM defined by ATS criteria and progressive lung disease who had been treated with rapamycin for longer than one year were included in the study. The mean age at the start of treatment was 43.6 (standard deviation 8.2) years and the mean duration of treatment 35.8 (SD 18) months equating to 143 patient/years of treatment observation. Mean pre-treatment FEV₁ was 52% (19) and DL_{CO} 42% (12) of the predicted values. Nine (19%) had TSC, 18 (38%) had a history of pneumothorax, angiomyolipoma was present in nine (19%) and lymphatic complications, defined as chylous collections or lymphatic masses visible on CT scanning, were also present in nine (19%) individuals.

Effect of rapamycin on Δ FEV₁

Twenty-one of the 47 individuals also had more than one year of observation of lung function prior to treatment with rapamycin. The remaining 26 had been treated elsewhere or required treatment at diagnosis and pre-treatment data were not available. There was no significant difference in age, baseline lung function or response lung function response to rapamycin within those with and without pre-treatment data. Within these 21, the mean duration of observation was 38 (SD 22) and 36 (SD 20) months pre and post treatment respectively. Mean pre-treatment Δ FEV₁ was -150 ml/yr (95% CI -220 to -79) and

during treatment was +35 ml/yr (95% CI +9 to +61. $p < 0.0001$). Furthermore, loss of FEV₁ improved during rapamycin treatment in all individuals (Figure 1a).

For all 47 subjects, mean treatment Δ FEV₁ was +11 (SD 75) ml/yr although between individuals Δ FEV₁ varied from +254 to -148 ml/yr. To understand the characteristics associated with differing responses to rapamycin, subjects were analysed in two ways. First, subjects were divided into quartiles according to their treatment Δ FEV₁ (Figure 1b). The 25% of those with the highest positive Δ FEV₁ when treated with rapamycin (quartile 1) had significantly higher pre-treatment FEV₁ and shorter disease duration than the 25% of those with the lowest negative Δ FEV₁ (quartile 4). There was no significant association with serum rapamycin level (Figure 1c), the presence of angiomyolipoma, pneumothorax or lymphatic complications (Table 1). Those with the highest or lowest values of Δ FEV₁ tended to have periods of observation of less than three years (Figure 1d). Next, the relationship between Δ FEV₁ and pre-treatment disease duration, pre-treatment FEV₁ and DL_{CO} were subjected to multivariate analysis for all subjects. In initial univariate analyses, disease duration (unadjusted $p = 0.02$), baseline FEV₁ (unadjusted $p = 0.006$) were associated with treatment response, although baseline DL_{CO} was not (unadjusted $p = 0.33$). Neither disease duration nor baseline FEV₁ remained significant in a subsequent multivariate analysis.

To determine if the lack of association between serum rapamycin levels and treatment response was due to maintaining higher serum drug levels in those with more severe disease, we examined the association between rapamycin level and baseline lung function. There was a slight negative correlation between rapamycin level over one year and baseline FEV₁ ($r = -0.37$ (95% confidence interval -0.62 to -0.048), $p = 0.026$) but not DL_{CO} ($r = -0.28$ (95% confidence interval -0.56 to 0.054), $p = 0.099$).

Side effects of rapamycin

Due to follow up schedules, intercurrent illness and travel issues to the LAM centre, eleven subjects had some missing values for rapamycin levels or side effects and these subjects were excluded from the side effect profile analysis. Most individuals experienced side effects which required a dose reduction in 25% of cases although all continued with treatment. The most common side effects were aphthous ulcers, nausea, acne, oedema and menstrual irregularities (Table 2). Within the first month of therapy aphthous ulcers, nausea and diarrhoea were most common. These fell from 59, 32 and 24% after one month to 15, 7 and 2% respectively after one year of therapy (Figure 2a). The incidence of acne, oedema and menstrual irregularities tended to increase over the first year of therapy from 7, 5 and 0% respectively at one month to 17, 12 and 7% of individuals respectively at 12 months. By the end of the observation period (mean treatment duration of 35.8 months), the prevalence of all side effects was 5% or less in all those treated. Pneumonitis was not observed at any time.

Relationship between side effects and rapamycin level

We next examined the association between serum rapamycin level and the six most common side effects over the first month and first 12 months of treatment. After one month, 40% of those with a rapamycin level <3 pg/ml developed aphthous ulcers but none of the other six common side effects. During the first month of treatment, aphthous ulcers and diarrhoea were associated with increasing rapamycin levels (Figure 2b). An increasing incidence of aphthous ulcers and diarrhoea was also associated with higher mean serum rapamycin levels over one year, as were nausea, acne and menstrual irregularities (Figure 2c). Whilst the prevalence of individual side effects for differing rapamycin levels did not allow statistical analysis the total occurrence of the six major side effects was positively correlated with mean rapamycin level over one year ($r=0.39$, $p=0.02$).

Effect of rapamycin on laboratory values

Treatment with rapamycin was associated with a significant elevation of serum cholesterol within the first month of treatment from a baseline of 5.1 mmol/l (95% CI 4.8-5.4) to 5.6 (95% CI 5.2-6.0) which was sustained for the whole duration of treatment (Figure 3a). Urinary PCR was variable between individuals although there was a trend toward an increase PCR over the first year of treatment this returned to pre-treatment values over the course of treatment (mean duration 35 months. Figure 3a). There were no significant changes in haemoglobin, renal or liver function over the treatment period (data not shown).

Although those with higher plasma rapamycin levels tended to have the larger elevations of serum cholesterol, the serum level of rapamycin over 12 months of treatment was not significantly related to the increase in either cholesterol or urine PCR (Figure 3b).

Discussion

We have examined the lung function response to rapamycin and related side effects in a prospective national cohort of women with progressive lung disease due to LAM. Overall, rapamycin was associated with reduced disease progression but a significant minority continued to lose lung function at an accelerated rate. Whilst side effects were common, particularly at higher doses of rapamycin, they did not require cessation of therapy and remained at tolerable levels over several years. Likewise, elevations in serum cholesterol and proteinuria were small and manageable.

In all cases, treatment with rapamycin was associated with improvements in ΔFEV_1 . In this study the mean ΔFEV_1 , observed for almost three years of treatment was +11 ml/yr and similar to that observed over shorter periods and in other cohorts^{5 14}. What is striking is the variability in post treatment ΔFEV_1 which although observed in other studies, has not been previously addressed. Those with the most favourable values of ΔFEV_1 tended to have had LAM for less time and had better lung function, particularly FEV_1 , at the start of treatment, importantly this favourable lung function response was not simply accounted for by higher rapamycin levels in this group. It is possible that those with the least response to rapamycin have disease that is less dependent on mTOR dysregulation as suggested by the finding that signalling pathways other than mTOR contribute to tumourigenesis in LAM cells²⁰. In addition, VEGF-D is synthesised by LAM cells and is a transcriptional target of mTOR: the finding that higher levels of serum VEGF-D are associated with a better response to rapamycin is potentially consistent with differing levels of mTOR dysregulation and influence on the disease phenotype between individuals²¹. Conversely, resistance to rapamycin may be acquired over time as occurs in breast cancer cells *in vitro*²²: with potential mechanisms including cellular efflux of rapamycin by ATP binding cassette transporters, mutations in rapamycin binding proteins, including FKBP, or loss of function or feedback in pathways such as Akt and retinoblastoma protein mediating some rapamycin dependent growth effects^{23 24}. It is also possible that in more advanced disease, LAM related tissue remodelling itself, including recruitment of wild type cells can support LAM nodule growth and lung destruction, independent of mTOR signalling²⁵. LAM is variable both in severity and its clinical manifestations and it is conceivable that specific LAM phenotypes, or groups of clinical features may be associated with favourable or unfavourable responses to rapamycin. The finding that those with the most and least favourable responses had different pre-treatment characteristics, but these characteristics were not significant in across the group as a whole, suggests those with good or poor responses to mTOR inhibition have different phenotypes or drug sensitivity rather than all patients being part of a continuous spectrum of rapamycin responsiveness, although larger prospective studies will be required to address this point definitively. Previous reports have suggested that those with chylous complications respond well to rapamycin¹¹ and although in our study, those with positive values of ΔFEV_1 had more lymphatic disease than those with negative ΔFEV_1 values, this was not significantly different overall. It is possible the benefit obtained from rapamycin in lymphatic remodelling leading to reductions in lymphatic masses and chylous collections does not translate into longer term effects on lung parenchymal damage. However our study was not powered to definitively assess the association of individual or groups of clinical features and treatment response.

We were interested to observe that there was no association between ΔFEV_1 and serum rapamycin level. Although there was a weak association between serum rapamycin level and lower FEV_1 at the start of therapy, we cannot completely exclude the possibility that the lack of a dose response relationship was due

to this, although the level of difference is unlikely to have influenced the findings significantly. Our findings would be consistent with the idea that serum levels greater than 2 pg/ml are sufficient to treat progressive lung disease in most women with LAM. Whilst most clinical trials of rapamycin showing benefits on lung function and angiomyolipoma have titrated serum levels to 5 - 10 pg/ml, a retrospective study has suggested that lower serum rapamycin levels may be equally effective²⁶. Our study, examining the group as a whole, was unable to assess if there was a dose response relationship between rapamycin level and ΔFEV_1 for individual subjects, however, this study would require very long periods of observation and has not yet been performed.

Side effects were common and tended to occur either at the start of treatment and reduce over time (mouth ulcers, nausea and diarrhoea) or some weeks into treatment and persist (acne, oedema, menstrual disturbance). In excess of one year of treatment, individual side effects occurred in less than five percent of individuals overall. Unlike lung function response, there was a relationship between side effects and serum rapamycin levels with mean serum level positively associated with the six most common side effects over one year with nausea and diarrhoea particularly increasing at higher serum levels. Changes in laboratory indices mainly comprised a persistent elevation in serum cholesterol and transient proteinuria but in no individuals resulted in the need to stop therapy. There was no clear correlation between rapamycin level and elevation in either urinary protein or serum cholesterol.

Our study was a real world observational cohort of those receiving rapamycin for progressive lung disease. As the Centre provides care for over two thirds of the UK population with a range of ages, clinical phenotypes and severity the study benefitted from being an unselected group representative of the disease as a whole¹⁵. Subjects were treated according to a standard protocol and seen at all visits by the same clinical team and had lung function measured at the same centre. However, various limitations are inherent real-world cohorts, side effect reporting relied on patient recall and treatment duration was not the same for all participants. As a consequence, extremes of ΔFEV_1 where values exceeded 100 ml/yr in either direction, tended to be those with a duration of observation of less than three years suggesting some of this variability may be attributed to shorter term variation or regression to the mean¹⁹. However even in those treated for longer periods there was still significant variability in response. As rapamycin has become the standard of care from those with progressive lung disease it is no longer possible to study untreated control subjects matched for disease severity. However these subjects had similar overall levels of base line lung function, lung function response and side effects seen in other studies including the MILES trial, a one year randomised placebo controlled trial of rapamycin^{5 14}. Although serum rapamycin level and baseline lung function were not examined in the MILES trial, MILES has been the only other study to examine variability in response to rapamycin where a poorer response over one year was associated with low baseline serum VEGF-D values, perhaps consistent with less mTOR dependent disease^{5 21}.

Our findings have clinical implications and suggest that lower serum rapamycin levels are associated with fewer side effects but no reduction in efficacy with potential benefits in reduced long term toxicity and costs. The observation that better responses were associated with earlier disease is consistent with the idea that early intervention with low dose rapamycin may be the best way to preserve lung function. The decision on when to offer treatment with rapamycin to balance preservation of lung function against cumulative side effects, and indeed the risk of unnecessary treatment of some individuals, is a critical issue for physicians and women with LAM. The recent ATS/JRS statement recommends the introduction of treatment for those with FEV₁ or DL_{CO} <70% of the predicted value¹². It is currently not known how best to identify those with active disease earlier in their natural history. Those with active disease may include those with falling FEV₁ whilst still in the normal range, those with normal spirometry but impaired DL_{CO} or exertional hypoxaemia. In addition, higher levels of VEGF-D and younger age at presentation are more likely to indicate active disease and benefit from early treatment. The use of lower doses of rapamycin than previously studied with the aim of preserving lung function in early disease is to be tested in a randomised clinical trial (ClinicalTrials.gov Identifier: NCT03150914). It is also important to recognise that some treated with rapamycin continue to lose lung function at an accelerated rate and a formal study of disease phenotypes associated with poor lung function response and a protocol considering adjunctive therapy to rapamycin would improve management of individuals with aggressive and less mTOR inhibitor responsive disease although would require international collaboration.

Table 1. Clinical characteristics of quartiles of Δ FEV₁ response to rapamycin

ΔFEV₁ response quartile	Q1	Q2	Q3	Q4	Q1 vs Q4 (p=)
n	11	12	12	12	
Rapamycin treated ΔFEV₁					
range (ml/yr)	254 to 56	50 to 0	-1 to -30	-31 to -148	-
mean (ml/yr)	111 (58)	28 (15)	-17 (11)	-71 (41)	<0.0001
duration of treatment (yrs)	2.4 (1.3)	3.4 (1.6)	2.8 (1.1)	2.4 (2.1)	0.09
Clinical characteristics at start of treatment					
pre-treatment Δ FEV ₁ (ml/yr) [†]	-186 (238)	-100 (69)	-152 (77)	-53 (202)	0.20
age (yrs)	41 (9)	45 (11)	44 (8)	45 (6)	0.13
disease duration (yrs)	6.1 (5.3)	13.0 (10.2)	8.2 (5.0)	11.3 (5.9)	0.02
FEV ₁ (% predicted)	67 (23)	42 (10)	52 (17)	48 (20)	0.02
DL _{CO} (% predicted)	46 (11)	40 (10)	45 (14)	40 (15)	0.13
Disease features present					
angiomyolipoma	6	5	6	3	NS
lymphatic disease	3	3	1	2	NS
TSC	3	2	2	2	NS
ever had pneumothorax	5	4	6	3	NS
Post treatment laboratory values					
trough rapamycin level (ng/ml)*	4.2 (1.2)	5.2 (1.2)	5.6 (1.7)	5.2 (1.5)	0.07
urine protein/creatinine ratio**	8 (5-366)	9 (6-43)	11 (5-79)	8 (6-15)	0.84

[†] for 21 subjects only. * mean value over 12 months (p for t-test). ** median (range) value after 12 months (p for Mann-Whitney test). NS for non-parametric data analysed by Chi square and Fischer's exact test.

Table 2. Side effects experienced whilst taking rapamycin according to duration of treatment and categorised by the Common Terminology Criteria for Adverse Events.

	% affected				
Treatment duration (months)	1	6	12	latest	ever
Common Terminology Criteria for Adverse Events Category					
Gastrointestinal					
Oral mucositis	58	35	24	13	65
Diarrhoea	32	12	10	0	41
Nausea	24	3	5	0	24
Abdominal pain	6	0	0	0	6
Indigestion	6	0	0	0	6
Bloating	0	3	5	6	9
Reflux symptoms	0	0	0	5	5
Dermatologic					
Acne	6	17	18	0	41
Rash	3	10	0	0	12
Dry skin	6	0	0	0	6
Soft tissues					
Peripheral oedema	5	7	0	0	9
Sexual or reproductive function					
Menstrual cycle disturbances	0	7	5	0	15
Constitutional symptoms					
Fatigue	3	7	0	5	9
Infection					
Upper respiratory / bronchitis	12	24	10	13	35
Tonsillitis	3	7	0	0	6
Pneumonia	0	3	0	5	5
Urinary tract infection	0	7	0	0	6
Skin infection	3	7	0	0	9
Musculoskeletal					
Arthralgia or myalgia	3	3	5	0	6

Figure legends.

Figure 1. Change in FEV₁ in response to rapamycin. (a) Loss of FEV₁ (Δ FEV₁) in individuals prior to and during treatment with rapamycin. Δ FEV₁ improved in all of those treated and was significant in the group as a whole. (b) Variation in Δ FEV₁ between 47 individuals treated with rapamycin. (c) Lung function response to rapamycin (Δ FEV₁) is not related to mean serum rapamycin level over one year. (d) Relationship between Δ FEV₁ and duration of rapamycin treatment. Outlying values of Δ FEV₁ tend to be associated with shorter durations of observation.

Figure 2. Side effects of rapamycin treatment. (a) Relationship between side effects and treatment duration. Colours of markers and side effects are consistent in subsequent figures. (b) Side effects according to rapamycin level after one month of therapy. (c) Side effects according to rapamycin level after one year.

Figure 3. Effect of rapamycin on serum cholesterol and urine protein. (a) Mean and standard error of plasma cholesterol and urine protein / creatinine ratio (PCR) during treatment. (b) Association of serum rapamycin level with serum cholesterol and urine PCR after one year of therapy.

References

1. Johnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. *Clinics in Chest Medicine* 2016;**37**(3):389-403.
2. Harknett EC, Chang WYC, Byrnes S, et al. Regional and National Variability Suggests Underestimation of Prevalence of Lymphangioleiomyomatosis. *Quarterly Journal of Medicine* 2011;**104**(11): 971-79.
3. Finlay G. The LAM cell: what is it, where does it come from, and why does it grow? *Am J Physiol Lung Cell Mol Physiol* 2004;**286**(4):L690-93.
4. Lam HC, Nijmeh J, Henske EP. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. *The Journal of pathology* 2017;**241**(2):219-25.
5. McCormack FX, Inoue Y, Moss J, et al. Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. *New England Journal of Medicine* 2011;**364**:1595-606.
6. Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. *European Respiratory Journal* 2015;**46**(3):783-94.
7. Takada T, Mikami A, Kitamura N, et al. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. *Annals of the American Thoracic Society* 2016;**13**(11):1912-22.
8. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. *N Engl J Med* 2008;**358**(2):140-51.
9. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 trial. *Clinical Cancer Research* 2011;**17**(12):4071-81.
10. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet* 2013;**381**(9869):817-24.
11. Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in Lung Function and Chylous Effusions in Patients With Lymphangioleiomyomatosis Treated With Sirolimus. *Annals of Internal Medicine* 2011;**154**(12):797-805.
12. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. *American Journal of Respiratory and Critical Care Medicine* 2016;**194**(6):748-61.
13. Krueger DA, Northrup H. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatric Neurology* 2013;**49**(4):255-65.
14. Yao J, Taveira-DaSilva AM, Jones AM, et al. Sustained Effects of Sirolimus on Lung Function and Cystic Lung Lesions in Lymphangioleiomyomatosis. *American Journal of Respiratory and Critical Care Medicine* 2014.
15. Bee J, Bhatt R, McCafferty I, et al. Audit, research and guideline update: A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre. *Thorax* 2015.
16. Sasongko TH, Ismail NFD, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. *Cochrane Database of Systematic Reviews* 2016(7).
17. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. *European Respiratory Journal* 2005;**26**(1):153.
18. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party. Standardization of lung function tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. *Eur Respir J* 1993;**6**:5 - 40.
19. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. *Am J Respir Crit Care Med* 1999;**160**(2):628-33.
20. D'Armiento J, Shiomi T, Marks S, et al. Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation. *Cancer Research* 2016;**76**(4):844-54.

21. Young LR, Lee H-S, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *The Lancet Respiratory Medicine* 2013.
22. Noh W-C, Mondesire WH, Peng J, et al. Determinants of Rapamycin Sensitivity in Breast Cancer Cells. *Clinical Cancer Research* 2004;**10**(3):1013.
23. Sabatini DM. mTOR and cancer: insights into a complex relationship. *Nat Rev Cancer* 2006;**6**(9):729-34.
24. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. *British Journal of Cancer* 2006;**95**(8):955-60.
25. Clements D, Dongre A, Krymskyaya V, et al. Wild Type Mesenchymal Cells Contribute to the Lung Pathology of Lymphangioleiomyomatosis. *PLoS ONE* 2015.
26. Ando K, Kurihara M, Kataoka H, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. *Respiratory Investigation* 2013.